Julien Dômont

10.0k total citations · 2 hit papers
108 papers, 4.4k citations indexed

About

Julien Dômont is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Julien Dômont has authored 108 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 26 papers in Gastroenterology. Recurrent topics in Julien Dômont's work include Sarcoma Diagnosis and Treatment (43 papers), Gastrointestinal Tumor Research and Treatment (26 papers) and Vascular Tumors and Angiosarcomas (14 papers). Julien Dômont is often cited by papers focused on Sarcoma Diagnosis and Treatment (43 papers), Gastrointestinal Tumor Research and Treatment (26 papers) and Vascular Tumors and Angiosarcomas (14 papers). Julien Dômont collaborates with scholars based in France, Italy and United States. Julien Dômont's co-authors include Sylvie Bonvalot, Axel Le Cesne, C. Le Péchoux, Jean‐Yves Blay, Axel Le Cesne, Alessandro Gronchi, Olivier Mir, Mario Campone, Émilie Le Rhun and Paolo G. Casali and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Julien Dômont

105 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

2012 522 citations Thomas Bachelot, Gilles Romieu et al. The Lancet Oncology profile →
Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients

2017 322 citations Fabrice Denis, Julien Dômont et al. profile →

Peers

Countries citing papers authored by Julien Dômont

Since Specialization

Citations

This map shows the geographic impact of Julien Dômont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Dômont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Dômont more than expected).

Fields of papers citing papers by Julien Dômont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Dômont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Dômont. The network helps show where Julien Dômont may publish in the future.

Co-authorship network of co-authors of Julien Dômont

This figure shows the co-authorship network connecting the top 25 collaborators of Julien Dômont. A scholar is included among the top collaborators of Julien Dômont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Dômont. Julien Dômont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial 2023 ·Clinical Cancer Research ·Tobias Keßler, Daniel Schrimpf, (unknown), (unknown), Leon D. Kaulen, (unknown), Martin J. van den Bent, Martin Taphoorn, Alba A. Brandes, Ahmed Idbaïh, Julien Dômont, Paul M. Clément, Mario Campone, Martin Bendszus, Andreas von Deimling, Felix Sahm, Michael Platten, Wolfgang Wick, Antje Wick	11
2	Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer 2019 ·Journal of Thoracic Oncology ·T. Lizée, Ethan Basch, P. Trémolières, Éric Voog, Julien Dômont, (unknown), T. Urban, Jaafar Bennouna, Anne-Lise Septans, (unknown), B. Detournay, Fabrice Denis	81
3	Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients 2017 ·Cancer/Radiothérapie ·Antoine Schernberg, F. Dhermain, Samy Ammari, Sarah Dumont, Julien Dômont, Anna Patrikidou, Johan Pallud, Edouard Dezamis, Éric Deutsch, G. Louvel	15
4	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial 2015 ·The Lancet Oncology ·Axel Le Cesne, Jean‐Yves Blay, Julien Dômont, Emmanuelle Tresch‐Bruneel, Christine Chevreau, François Bertucci, Corinne Delcambre, Esma Saâda-Bouzid, Sophie Piperno‐Neumann, Jacques‐Olivier Bay, Olivier Mir, Isabelle Ray‐Coquard, Thomas Ryckewaert, Thibaud Valentin, Nicolás Isambert, Antoîne Italiano, Stéphanie Clisant, Nicolas Penel	63
5	Toward a new strategy in desmoid of the breast? 2015 ·European Journal of Surgical Oncology ·(unknown), Chafika Mazouni, Françoise Rimareix, Charles Honoré, Philippe Terrier, Olivier Mir, Julien Dômont, C. Le Péchoux, Axel Le Cesne, Sylvie Bonvalot	21
6	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence 2013 ·Cancer ·Chiara Colombo, Rosalba Miceli, Alexander J. Lazar, Federica Perrone, Raphael E. Pollock, Axel Le Cesne, Henk H. Hartgrink, Anne‐Marie Cleton-Jansen, Julien Dômont, Judith V.M.G. Bovée, Sylvie Bonvalot, Dina Lev, Alessandro Gronchi	132
7	Epithelioid Sarcoma: Need for a Multimodal Approach to Maximize the Chances of Curative Conservative Treatment 2013 ·Annals of Surgical Oncology ·Antonin Lévy, C. Le Péchoux, Philippe Terrier, (unknown), Julien Dômont, Olivier Mir, (unknown), Charles Honoré, Axel Le Cesne, Sylvie Bonvalot	33
8	GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study 2013 ·Annals of Oncology ·Antoîne Italiano, Axel Le Cesne, Carine Bellera, Sophie Piperno‐Neumann, Florence Duffaud, Nicolas Penel, Philippe A. Cassier, Julien Dômont, Naoko Takebe, Michèle Kind, J.M. Coindre, Jean‐Yves Blay, B. Bui	66
9	The treatment of desmoid tumors: a stepwise clinical approach 2012 ·Annals of Oncology ·Sylvie Bonvalot, Archita P. Desai, Sara Coppola, C. Le Péchoux, Philippe Terrier, Julien Dômont, Axel Le Cesne	124
10	High-dose ifosfamide (HDI) in metastatic synovial sarcoma: The Institut Gustave Roussy experience. 2012 ·Journal of Clinical Oncology ·(unknown), Angela Cioffi, (unknown), Julien Dômont, Aurore Blesius, Anna Patrikidou, Sylvie Bonvalot, C. Le Péchoux, Philippe Terrier, (unknown), Émilie Lanoy, Axel Le Cesne	5
11	Epithelioid Hemangioendothelioma of the Femoral Vein in a 22 Year Old Female 2012 ·European Journal of Vascular and Endovascular Surgery ·(unknown), Julien Dômont, Alexandros Mallios, S. Bonvalot, (unknown)	1
12	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study breakdown → 2012 ·The Lancet Oncology ·Thomas Bachelot, Gilles Romieu, Mario Campone, Véronique Dièras, Claire Cropet, Florence Dalenc, Marta Jimenez, Émilie Le Rhun, Jean‐Yves Pierga, Anthony Gonçalvès, Marianne Leheurteur, Julien Dômont, Maya Gutierrez, Hervé Curé, Jean-Marc Ferrero, C. Labbé-Devilliers	522
13	Radiothérapie avec modulation d’intensité dans le traitement postopératoire des sarcomes rétropéritonéaux : profil de toxicité aiguë 2011 ·Cancer/Radiothérapie ·A. Paumier, Sylvie Bonvalot, A. Beaudré, Philippe Terrier, Françoise Rimareix, Julien Dômont, Axel Le Cesne, (unknown), Dimitri Lefkopoulos, C. Le Péchoux	2
14	Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour 2009 ·Investigational New Drugs ·Julien Dômont, Christophe Massard, Nathalie Lassau, Jean‐Pierre Armand, Axel Le Cesne, Jean‐Charles Soria	41
15	The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma 2009 ·Annals of Oncology ·David Planchard, Julien Dômont, E. Taranchon, I. Monnet, Jean Trédaniel, (unknown), Pierre Validire, Benjamin Besse, Jean‐Charles Soria, P Fouret	16
16	Imatimid-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases 2007 ·Skeletal Radiology ·D. Vanel, Sylvie Bonvalot, C. Le Péchoux, Angela Cioffi, Julien Dômont, A. Le Cesne	7
17	Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer 2007 ·Annals of Oncology ·Laurent Taillade, Frédérique Penault‐Llorca, Thomas Boulet, P Fouret, Stefan Michiels, E. Taranchon, Giannis Mountzios, Pierre Validire, Julien Dômont, Philippe Girard, Dominique Grunenwald, Thierry Le Chevalier, (unknown)	51
18	Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer 2006 ·Anti-Cancer Drugs ·Valérie Martinez, Olivier Mir, Julien Dômont, Didier Bouscary, François Goldwasser	4
19	Telomeres and telomerase as targets for anticancer drug development 2006 ·Critical Reviews in Oncology/Hematology ·Ken A. Olaussen, Karine Dubrana, Julien Dômont, Jean‐Philippe Spano, Laure Sabatier, Jean‐Charles Soria	76
20	Adjuvant Chemotherapy in Early-Stage Non-Small Cell Lung Cancer 2005 ·Seminars in Oncology ·Julien Dômont, Jean‐Charles Soria, Thierry Le Chevalier	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact